Who Paid My Doc
Eric Schaefer
Hematology & Oncology Fayetteville, AR Medical Doctor
NPI 1558325118 CMS profile 464579
3232 N Northhills Blvd, Fayetteville, AR 72703
General payments
$465,814
Research payments
$2,935
Ownership & investment interest
$77,600
Research they led as principal investigator
$4,687,368
Through program year 2025, Eric Schaefer of Fayetteville, AR is reported in the CMS Open Payments database as having received $465,814 across 977 general payments and $2,935 in research payments paid to them. Separately, studies naming them as principal investigator received $4,687,368 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $77,600 across 7 holdings.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 98th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
13 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $148,212 | 158 | |
| 2024 | General | $60,660 | 126 | |
| 2023 | General | $119,445 | 182 | |
| 2022 | General | $76,379 | 140 | |
| 2022 | Research | $2,835 | 4 | |
| 2021 | General | $24,369 | 95 | |
| 2020 | General | $34,373 | 133 | |
| 2020 | Research | $100 | 1 | |
| 2019 | General | $2,376 | 143 | |
| 2025 | Ownership | $25,650 | 2 | |
| 2024 | Ownership | $25,650 | 2 | |
| 2023 | Ownership | $25,650 | 2 | |
| 2022 | Ownership | $650 | 1 |
Beside peers
- Eric Schaefer
- Hematology & Oncology median
- Middle half of Hematology & Oncology
- National median
In program year 2025, general payments to Eric Schaefer were reported at $148,212. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.
Show as a table
| Year | Eric Schaefer | Hematology & Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $2,376 | $529 | $121–$2,516 | $163 |
| 2020 | $34,373 | $339 | $82–$2,213 | $114 |
| 2021 | $24,369 | $263 | $49–$1,965 | $132 |
| 2022 | $76,379 | $416 | $103–$2,395 | $149 |
| 2023 | $119,445 | $542 | $125–$2,646 | $160 |
| 2024 | $60,660 | $692 | $141–$3,008 | $164 |
| 2025 | $148,212 | $683 | $143–$3,154 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 67 drugsPart D claims
2,552
Drug cost
$3,633,691
Branded share of claims
29.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Jakafi Ruxolitinib Phosphate | Brand | 65 | $1,002,651 | |
| Ojjaara Momelotinib Dihydrochloride | Brand | 20 | $567,963 | |
| Tagrisso Osimertinib Mesylate | Brand | 26 | $492,288 | |
| Revlimid Lenalidomide | Brand | 28 | $481,587 | |
| Xtandi Enzalutamide | Brand | 31 | $444,705 | |
| Calquence Acalabrutinib Maleate | Brand | 16 | $234,584 | |
| Brukinsa Zanubrutinib | Brand | 13 | $183,562 | |
| Xarelto Rivaroxaban | Brand | 106 | $80,223 | |
| Venclexta Venetoclax | Brand | 14 | $61,643 | |
| Eliquis Apixaban | Brand | 58 | $38,903 |
The 10 drugs with the highest cost, of 67 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 308 billing codesPaid by Medicare
$5,080,054
Medicare patients
1,492
Services billed
313,522
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Cancer | 49% | |
| Arthritis | 48% | |
| Ischemic heart disease | 37% | |
| Chronic kidney disease | 31% | |
| Diabetes | 29% | |
| COPD | 29% | |
| Depression | 27% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, pembrolizumab, 1 mg J9271 | Office | 49 | 23,200 | $1,029,971 |
| Injection, nivolumab, 1 mg J9299 | Office | 23 | 10,820 | $265,267 |
| Injection, denosumab, 1 mg J0897 | Office | 86 | 10,080 | $207,708 |
| Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg J1561 | Office | 33 | 4,236 | $163,710 |
| Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg Q5126 | Office | 14 | 3,060 | $140,840 |
| Injection, rituximab-arrx, biosimilar, (riabni), 10 mg Q5123 | Office | 18 | 2,270 | $71,510 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units J0885 | Office | 52 | 6,240 | $38,839 |
| Injection, ferric derisomaltose, 10 mg J1437 | Office | 22 | 2,200 | $35,754 |
| Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram Q5125 | Office | 28 | 29,040 | $10,832 |
| Injection, pemetrexed, 10 mg J9305 | Office | 16 | 2,525 | $8,667 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
First 5 of 42 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| INQOVI |
|
$1,110 | — | — |
| LYNPARZA |
|
$531 | — | — |
| LIBTAYO |
|
$167 | — | — |
| ENHERTU |
|
$158 | — | — |
| RYBREVANT |
|
$136 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See more in the dashboard: 25 with a free account, all 42 with PatronRecords
982 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Hematology & Oncology in Arkansas
Frits Van Rhee
Hematology & Oncology · Little Rock, AR
Isam Abdel-Karim
Hematology & Oncology · Fort Smith, AR
Appalanaidu Sasapu
Hematology & Oncology · Little Rock, AR
Stephan Rosenfeld
Hematology & Oncology · Fayetteville, AR
Stephen Divers
Hematology & Oncology · Hot Springs, AR
Humdum Durrani
Hematology & Oncology · Fort Smith, AR
Related records
Hematology & Oncology in Arkansas
Practitioners in the same specialty and state, ranked by reported value.
All Hematology & Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Arkansas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.